Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Bepranemab in Progressive Supranuclear Palsy
NCT04185415Phase 1Completed
- Sponsor
- UCB
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing bepranemab with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events at Week 68. Started Dec 2019; status: completed.
02
Drugs
Bepranemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT04185415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185415.